Breztri Aerosphere® is a long-term medicine to treat COPD and give patients better breathing, improve COPD symptoms and ...

AstraZeneca Pharma India rose 1.84% to Rs 6,515.50 after the durg maker said that it will launch Breztri Aerosphere in January 2025 in India.

This combination drug is used to treat chronic obstructive pulmonary disease in adults, relieving symptoms and preventing ...

The combination medication is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) to ...

The pharma major wants to bring innovative medicines to India faster, while increasing the access to its mass-market products ...

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid a probe that has battered the drugmaker’s share price. Chief ...

AstraZeneca’s Symbicort inhaler accounts for most of its inhalation portfolio revenue, projected by GlobalData to generate a total $2.5bn in 2024. Meanwhile GSK's lead inhalers include Trelegy ...

AstraZeneca's Q3 sales rose 18% YoY to $13.6 billion Adjusted EPADS hit $1.04, exceeding expectations. U.S. investment of $3.5 billion announced to bolster research and manufacturing. AstraZeneca ...

AstraZeneca’s Symbicort inhaler accounts for most of its inhalation portfolio revenue, projected by GlobalData to generate a total $2.5bn in 2024. Meanwhile GSK’s lead inhalers include Trelegy Ellipta ...

Inhaler previously announced the details of their new album alongside their biggest ever UK tour. The Dublin four-piece will release their third studio effort Open Wide on 7th February and will ...

Leon Wang, executive vice president in charge of China and the broader Asian region, is being detained while the Chinese government is probing AstraZeneca employees, the company said Wednesday.